Advances in the management of psoriatic arthritis (Q38227264)

31 August 2017

Advances in the management of psoriatic arthritis (English)

1 reference

31 August 2017

Ignazio Olivieri

1

1 reference

31 August 2017

Salvatore D'Angelo

series ordinal

2

1 reference

31 August 2017

Carlo Palazzi

series ordinal

3

1 reference

31 August 2017

Angela Padula

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

8 July 2014

1 reference

Nature Reviews Rheumatology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

9

1 reference

31 August 2017

531-542

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.106

31 August 2017

0 references

cites work

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Metabolic disorders in patients with psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Th17 cells in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Dermatology screening tools: project update from the GRAPPA 2012 annual meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden Early Arthritis cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Classification and clinical assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The diagnosis and treatment of early psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Predictors for radiological damage in psoriatic arthritis: results from a single centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Development of a preliminary composite disease activity index in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Leflunomide in psoriatic arthritis: results from a large European prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Psoriatic arthritis: treatment strategies using biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Psoriatic arthritis: current therapy and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Pharmacoeconomic issues in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Remission in psoriatic arthritis: is it possible and how can it be predicted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Can we reduce the dosage of biologics in spondyloarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Ustekinumab associated with flares of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Effect of IL-17A blockade with secukinumab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Successful use of tocilizumab in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Clinical features and predictive factors in psoriatic arthritis-related uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

31 March 2020

12 December 2020

Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Beyond early diagnosis: occult psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Can we identify psoriatic arthritis early?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Treatment strategies for early psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Predictors of response to intra-articular steroid injection in psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Rituximab in psoriatic arthritis: an exploratory evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.106

Use of methotrexate in patients with psoriatic arthritis

31 March 2020

1 reference

12 December 2020

Psoriasis, psoriatic arthritis, or psoriatic disease?

1 reference

12 December 2020

[Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis]

1 reference

12 December 2020

The use of sulfasalazine in psoriatic arthritis: a clinic experience

1 reference

12 December 2020

2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis

1 reference

12 December 2020

Consensus on a core set of domains for psoriatic arthritis

1 reference

12 December 2020

Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire

1 reference

12 December 2020

Remission in psoriatic arthritis.

1 reference

12 December 2020

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

1 reference

12 December 2020

Longitudinal study of clinical and radiological progression in psoriatic arthritis

1 reference

12 December 2020

Progression in psoriatic arthritis: role of time varying clinical indicators

1 reference

12 December 2020

The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide.

1 reference

12 December 2020

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

1 reference

12 December 2020

Glucocorticoid treatment in spondyloarthritis

1 reference

12 December 2020

Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms

1 reference

12 December 2020

Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.

1 reference

12 December 2020

Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.

1 reference

12 December 2020

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

1 reference

12 December 2020

Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients

1 reference

12 December 2020

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

1 reference

12 December 2020

Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology

1 reference

12 December 2020

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.106

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference